Amplia Therapeutics (ASX:ATX) Accumulated Depreciation: A$-0.07 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ATX Amplia Therapeutics Ltd ASX:ATX
28 GF Score
Price A$0.15
! 2 Warning Signs
View Full Analysis

What is Amplia Therapeutics Accumulated Depreciation?

Amplia Therapeutics ASX:ATX -3.33% 28 Accumulated Depreciation is A$-0.07 Mil as of Mar. 2026. GuruFocus rates ASX:ATX with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Amplia Therapeutics's quarterly accumulated depreciation stayed the same from Mar. 2025 (A$0.00 Mil) to Sep. 2025 (A$0.00 Mil) but then increased from Sep. 2025 (A$0.00 Mil) to Mar. 2026 (A$-0.07 Mil).

Amplia Therapeutics's annual accumulated depreciation stayed the same from Mar. 2024 (A$0.00 Mil) to Mar. 2025 (A$0.00 Mil) but then increased from Mar. 2025 (A$0.00 Mil) to Mar. 2026 (A$-0.07 Mil).

Amplia Therapeutics Accumulated Depreciation Related Terms

Amplia Therapeutics Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics Accumulated Depreciation Chart

Amplia Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.08 0.00 0.00 -0.07

Amplia Therapeutics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.07
ASX:ATX
28GF Score
Amplia Therapeutics Ltd ASX:ATX
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amplia Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of A$-0.07 Mil mean?
Amplia Therapeutics (ASX:ATX) has a Accumulated Depreciation of A$-0.07 Mil as of Mar. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Amplia Therapeutics and its competitors.
Is Amplia Therapeutics' Accumulated Depreciation too high?
Amplia Therapeutics' current Accumulated Depreciation is A$-0.07 Mil. Overall, Amplia Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' Accumulated Depreciation compare to VRTX and REGN?
Amplia Therapeutics' Accumulated Depreciation of A$-0.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Amplia Therapeutics and its competitors. Amplia Therapeutics's current Accumulated Depreciation is A$-0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current Accumulated Depreciation of A$-0.07 Mil. The current Accumulated Depreciation is A$-0.07 Mil. Amplia Therapeutics' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current Accumulated Depreciation is A$-0.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amplia Therapeutics Business Description

Other Exchanges INNMF:USA
Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
28GF Score

Get the complete analysis for ASX:ATX

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.15
Price